Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) Target Price at $43.70

UroGen Pharma Ltd. (NASDAQ:URGN) has received an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $39.20.

URGN has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Tuesday. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday. They issued a “buy” rating and a $31.00 target price for the company.

Insider Activity

In related news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

A number of large investors have recently made changes to their positions in the business. RTW Investments LP increased its holdings in shares of UroGen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock worth $40,841,000 after buying an additional 47,447 shares during the last quarter. Toronto Dominion Bank bought a new position in UroGen Pharma in the 4th quarter worth about $18,628,000. Vestal Point Capital LP grew its stake in UroGen Pharma by 307.5% in the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after acquiring an additional 1,230,000 shares in the last quarter. Acorn Capital Advisors LLC purchased a new stake in shares of UroGen Pharma in the 4th quarter worth approximately $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of UroGen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after purchasing an additional 36,084 shares during the period. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Stock Performance

Shares of URGN opened at $10.08 on Wednesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a one year low of $9.78 and a one year high of $20.70. The company has a 50-day simple moving average of $10.73 and a two-hundred day simple moving average of $12.20. The firm has a market capitalization of $236.38 million, a PE ratio of -3.20 and a beta of 1.08.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.